DalsnaFinance

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Markets GlobeNewswire By GlobeNewswire 21 Jul 2026 11:00 1 min read
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Agios provides update on Phase 2 trial of tebapivat in sickle cell disease

Agios provides update on Phase 2 trial of tebapivat in sickle cell disease

Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.com

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.